Loading...

Brilliant Violet 421™ anti-human CD279 (PD-1) Antibody

Pricing & Availability
Clone
EH12.2H7 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, PDCD1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
EH12.2H7_BV421_1_040311
Human peripheral blood lymphocytes were stained with CD3 FITC and CD279 (clone EH12.2H7) Brilliant Violet 421™ (top) or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).
  • EH12.2H7_BV421_1_040311
    Human peripheral blood lymphocytes were stained with CD3 FITC and CD279 (clone EH12.2H7) Brilliant Violet 421™ (top) or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).
  • EH12.2H7_BV421_2_040311
Compare all formats See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
329919 25 tests 164€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329920 100 tests 322€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  16. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kim JH, et al. 2020. Sci Rep. 10:1835. PubMed
  2. Jiang W, et al. 2021. Sci Rep. 11:1864. PubMed
  3. Wei H, et al. 2022. Front Immunol. 13:1060695. PubMed
  4. Touizer E, et al. 2023. iScience. 26:105862. PubMed
  5. Wang P, et al. 2023. Front Immunol. 13:1104329. PubMed
  6. Statzu M, et al. 2023. Nat Microbiol. 8:299. PubMed
  7. Giles JR, et al. 2022. Immunity. 55:557. PubMed
  8. Jung IY, et al. 2022. Sci Transl Med. 14:eabn7336. PubMed
  9. Geetha H. Mylvaganam, Daniel Rios 2017. Proc Natl Acad Sci U S A. 114(8):1976-1981. PubMed
  10. Cheng DN, et al. 2023. Elife. 12:. PubMed
  11. Kim HS, et al. 2023. Front Cell Infect Microbiol. 13:1101291. PubMed
  12. Wang X, et al. 2023. Stem Cell Rev Rep. . PubMed
  13. Komech EA, et al. 2022. Front Immunol. 13:973243. PubMed
  14. Gibellini L, et al. 2020. EMBO Mol Med. 12:e13001. PubMed
  15. Mylvaganam G, et al. 2014. J Immunol. 193:4527. PubMed
  16. Claiborne DT, et al. 2019. PLoS Pathog. 15:e1007981. PubMed
  17. Whitney JB, et al. 2018. Nat Commun. 9:5429. PubMed
  18. Goncharov MM, et al. 2022. Elife. 11:. PubMed
  19. Wu VH, et al. 2020. JCI Insight. 5:00. PubMed
  20. Nielsen CM, et al. 2021. Cell Reports Medicine. 2(3):100207. PubMed
  21. Mastelic-Gavillet B, et al. 2019. J Immunother Cancer. 7:257. PubMed
  22. Hagan T, et al. 2020. Cell. 178(6):1313-1328.e13.. PubMed
  23. Parackova Z, et al. 2020. Sci Rep. 0.759027778. PubMed
  24. Gupta R, et al. 2022. Front Immunol. 13:886442. PubMed
  25. Wang Z, et al. 2021. Cell Mol Immunol. 18:2188. PubMed
  26. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  27. Calascibetta F, et al. 2016. J Virol. 90: 7541 - 7551. PubMed
  28. Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed
  29. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  30. Eberhardt K, et al. 2015. Clin Infect Dis. 61: 1615 - 1623. PubMed
  31. Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed
  32. Lindesmith LC, et al. 2020. Cell Mol Gastroenterol Hepatol. 0.586805556. PubMed
  33. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  34. Harper J, et al. 2022. J Clin Invest. . PubMed
  35. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  36. Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed
  37. Cui J, et al. 2020. Cancers (Basel). 0.596527778. PubMed
  38. Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
  39. van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed
  40. Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed
  41. Juno JA, et al. 2020. Nat Med. 26:1428. PubMed
  42. Bergamaschi L, et al. 2021. Immunity. 54(6):1257-1275.e8. PubMed
  43. Kreutmair S, et al. 2021. Immunity. . PubMed
  44. Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed
  45. Minagawa A, et al. 2018. Cell Stem Cell. 1.548611111. PubMed
  46. Xu L, et al. 2021. Front Oncol. 11:686156. PubMed
  47. Naidoo KK, et al. 2020. PLoS One. 15:e0242448. PubMed
  48. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  49. Seo IH, et al. 2021. Immune Netw. 21:e17. PubMed
  50. Minassian AM, et al. 2021. Med (N Y). 2:701. PubMed
  51. Miller IC, et al. 2021. Nature Biomedical Engineering. :. PubMed
  52. André P et al. 2018. Cell. 175(7):1731-1743 . PubMed
  53. Sayin I, et al. 2018. J Exp Med. 7:40286. PubMed
  54. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  55. El Ahanidi H, et al. 2022. Front Oncol. 11:795242. PubMed
  56. Buggert M, et al. 2014. J Immunol. 192:2099. PubMed
  57. Buggert M, et al. 2014. J Immunol. 192:4685. PubMed
  58. Cao J, et al. 2018. Nat Commun. 9:77. PubMed
  59. Lee SWL, et al. 2018. Front Immunol. 8:1064. PubMed
  60. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
  61. Jung JH, et al. 2021. Nat Commun. 12:4043. PubMed
  62. Pacheco Y, et al. 2013. J Immunol. 191:2072. PubMed
  63. Ferrando-Martinez S, et al. 2018. J Clin Invest. 128:2089. PubMed
  64. Rutishauser L, et al. 2017. AIDS Res Hum Retroviruses . 10.1089/AID.2016.0324. PubMed
  65. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  66. Zabaleta N, et al. 2021. Cell Host Microbe. :. PubMed
  67. Harper JL, et al. 2020. Nat Med. 519:26. PubMed
  68. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
  69. Routhu NK, et al. 2021. Immunity. 54(3):542-556.e9. PubMed
  70. Pilkinton MA, et al. 2017. Vaccine. 35:329. PubMed
  71. Horn C, et al. 2021. HIV Med. 22:397. PubMed
  72. Zebley CC, et al. 2021. Cell Rep. 37:110079. PubMed
  73. Lee J, et al. 2015. Clin Immunol. 159: 37-46. PubMed
  74. RY H, et al. 2016. Oncoimmunology. 6:e1249561. PubMed
  75. Bradley T, et al. 2020. Nat Commun. 11:948. PubMed
  76. Gannon PO, et al. 2020. Cytotherapy. 22(12):780-791. PubMed
  77. de Jonge K, et al. 2021. OncoImmunology. 10(1):1873585. PubMed
  78. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  79. Han Q, et al. 2020. Cell Rep. 30:1553. PubMed
  80. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  81. Leng T, et al. 2019. Cell Rep. 28:3077. PubMed
  82. Levin MJ, et al. 2018. J Clin Invest. 128:4429. PubMed
  83. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  84. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  85. Baxter AE, et al. 2017. Nat Protoc. 12:2029. PubMed
  86. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  87. Collinson–Pautz MR, et al. 2019. Leukemia. 33:2195. PubMed
  88. Karlsson J, et al. 2020. Nat Commun. 1.773611111. PubMed
  89. Claiborne D, et al. 2015. Proc Natl Acad Sci U S A. 112:1480. PubMed
  90. Riberdy JM, et al. 2020. Mol Ther Methods Clin Dev. 1.146527778. PubMed
  91. Suzuki S, et al. 2020. Cancer Sci. 1943:111. PubMed
  92. Guéguen P, et al. 2021. Sci Immunol. 6:. PubMed
  93. Nicholas K, et al. 2015. Cytometry A. 10.1002/cyto.a.22799. PubMed
  94. Paris R, et al. 2015. PLoS One. 10: 0144767. PubMed
  95. Kim N, et al. 2020. Nat Commun. 2.045138889. PubMed
RRID
AB_10900818 (BioLegend Cat. No. 329919)
AB_10900818 (BioLegend Cat. No. 329920)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Other Formats

View All CD279 Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 421™ anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC-F
FITC anti-human CD279 (PD-1) EH12.2H7 FC
PE anti-human CD279 (PD-1) EH12.2H7 FC,SB
APC anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 647 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP/Cyanine5.5 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Pacific Blue™ anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) (Maxpar® Ready) EH12.2H7 FC,CyTOF®
Brilliant Violet 605™ anti-human CD279 (PD-1) EH12.2H7 FC
Ultra-LEAF™ Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC-F
Brilliant Violet 711™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 785™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 510™ anti-human CD279 (PD-1) EH12.2H7 FC
Biotin anti-human CD279 (PD-1) EH12.2H7 FC
PE/Dazzle™ 594 anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 488 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP anti-human CD279 (PD-1) EH12.2H7 FC
GoInVivo™ Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC
Brilliant Violet 650™ anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 700 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Fire™ 750 anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-A0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-B0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-C0088 anti-human CD279 (PD-1) EH12.2H7 PG
Brilliant Violet 750™ anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-D0088 anti-human CD279 (PD-1) EH12.2H7 PG
PE/Fire™ 640 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine5 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Fire™ 744 anti-human CD279 (PD-1) EH12.2H7 FC
Spark Red™ 718 anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 570™ anti-human CD279 (PD-1) EH12.2H7 FC
Go To Top Version: 2    Revision Date: 01/22/2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account